Novavax names Brian Rosen VP of Government Affairs

Courtesy of globalnewswire.com
Novavax, Inc., a clinical-stage vaccine company that creates and markets recombinant nanoparticle vaccine and adjuvants, recently named Brian Rosen as its new vice president of Government Affairs and Policy.

In his new position, Rosen will be the leader behind policy efforts and government affairs that are vital to patients seeking accessibility to vaccines made by Novavax. Rosen will concentrate on the top product candidates in the company, such as the quadirvalent seasonal and pandemic flu vaccine candidates and the RSV vaccine franchise.

Rosen has more than 20 years of experience in patient advocacy and the medical industry. For most of those 20 years, he worked in policy work, reimbursement, advocacy and government affairs.

He previously held positions at the Leukemia & Lymphoma Society as the chief Policy, Advocacy and Patient Access Officer; and at MedImmune as the Government Affairs, Policy and Alliance Development chair.

"The health care landscape is constantly changing and supportive vaccine policy requires diligent attention and coordination in concert with Novavax' commercialization plans,” John Trizzino, senior vice president of Commercial Operations, said. “Brian's extensive experience, particularly with RSV and influenza, is critical to planning and executing a commercial launch of our vaccines. Brian is a key addition to our management team and brings valuable perspective that I am confident will contribute to bringing our novel vaccines to market."

Organizations in this Story


Want to get notified whenever we write about Novavax ?
Next time we write about Novavax, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.